
Common cough medicine could slow dementia in Parkinson's patients, study hints
Nearly half of those diagnosed with Parkinson's develop dementia within 10 years, with progressively worsening memory loss, confusion, hallucinations, and mood changes, which affect patients, families, and the healthcare system.
'Current therapies for Parkinson's disease and dementia address symptoms but do not stop the underlying disease,' said neurologist Stephen Pasternak from Western University in Canada.
Now, a new year-long clinical trial suggests that the cough medicine Ambroxol – used safely for decades in Europe – can potentially slow the development of these symptoms.
The small scale study, published in the journal JAMA Neurology, monitored 55 participants with Parkinson's dementia, assessing their memory, psychiatric symptoms, and the blood marker GFAP linked to brain damage.
One group of participants received Ambroxol daily while the other received a placebo.
Researchers found that the drug was safe, well-tolerated and reached therapeutic levels in the brain.
While psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol, scientists said in a statement.
'Individuals receiving placebo showed a clinically meaningful worsening in neuropsychiatric symptoms, whereas those receiving ambroxol remained stable,' researchers wrote in the study.
Those with high risk variants of a key gene linked to dementia showed improved cognitive performance on Ambroxol, they said.
GFAP levels increased in the placebo group, but stayed stable with Ambroxol, suggesting that the cough medicine may have the potential to protect the brain from faster deterioration under Parkinson's.
'Ambroxol was safe, well-tolerated, and demonstrated target engagement,' scientists wrote, however adding that the drug's clinical effect on cognition was 'not confirmed' in the study.
Previous studies have shown that Ambroxol supports a key enzyme called glucocerebrosidase (GCase), whose levels are low in Parkinson's patients.
Researchers previously found that Ambroxol could help treat the rare genetic disorder Gaucher disease in children, which is caused by a deficiency of GCase.
When this enzyme doesn't work properly, waste can build up in brain cells, leading to damage.
'These findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist,' Dr Pasternak said.
'If a drug like Ambroxol can help, it could offer real hope and improve lives,' he said.
While the cough medicine is approved in Europe for treating respiratory conditions, with a long-standing safety record, including use at high doses and during pregnancy, it is not approved for any use in the US or Canada.
Scientists hope the pharmacological data from this study could help conduct larger clinical trials to test the effectiveness of Ambroxol in slowing dementia symptoms.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
an hour ago
- BBC News
Nurses union to reject pay deal as strike vote looms
Nurses will overwhelmingly reject their pay award in England this week, raising the possibility of strikes later in the year, the BBC Royal College of Nursing (RCN) has been holding a consultative vote on their 3.6% pay rise, previously describing it as "grotesque" to award nurses a lower increase than doctors, teachers, prison officers and the armed decision on formal strike action would not be made until later in the government accepted in May the pay review body's recommendations of a 3.6% rise for nurses this year. The union will announce the results of its indicative vote later this week but the BBC understands it will show an "overwhelming" rejection of the turnout is expected to be well over the 50% threshold needed for industrial union will demand ministers negotiate over the summer to avoid a formal ballot for strike action in the RCN is understood to be open to talks on wider pay structures, not just headline pay.A union spokesman said: "The results will be announced to our members later this week. As the largest part of the NHS workforce, nursing staff do not feel valued and the government must urgently begin to turn that around."On Friday the GMB union representing thousands of health workers, including ambulance crews, rejected the government's pay deal in an initial consultative GMB said its members voted by 67% against the 3.6% pay award offered for 2025/26 in union has written to Health Secretary Wes Streeting calling for an urgent meeting to discuss pay and other national secretary Rachel Harrison said: "Our national NHS and ambulance committees met on 24 July to discuss the ballot results and determine what the next steps should be."Today, we have written to Secretary of State Wes Streeting, asking him to meet with us to discuss pay and other issues of significant importance to GMB members."We await his reply with interest."Thousands of resident doctors in England, previously known as junior doctors, began a five-day strike on Friday after the government and the British Medical Association failed to reach an agreement over health secretary said while it was not possible to eliminate disruption to the NHS, it was being kept to a minimum.


The Guardian
an hour ago
- The Guardian
Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.


Times
4 hours ago
- Times
A woman has died after being licked by a dog. Here's what you need to know
They share our sofa and sprawl across our laps. But should we let our dogs lick us? Last week it emerged that June Baxter, 83, a retired legal secretary, died of septic shock after her leg injury was licked by a dog and this led to an infection. Tests from the wound found Pasteurella multocida, a bacteria present in about 50 per cent of dogs' mouths, which typically does a dog no harm. No, although very few incidents of serious injury or death caused by Pasteurella multocida from a dog lick have been recorded. They include an 85-year-old woman with a pet dog who had Pasteurella multocida and died with multiple organ failure after developing septic shock. In 2023 the case report authors in the journal BMC Geriatrics said that highlighting her death was 'important, given the growing cohort of elderly pet-owners seeking medical care'.